WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004006801) TREATMENT FOR DRY EYE SYNDROME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/006801    International Application No.:    PCT/US2003/022297
Publication Date: 22.01.2004 International Filing Date: 17.07.2003
Chapter 2 Demand Filed:    05.02.2004    
IPC:
A61K 31/07 (2006.01), A61K 31/20 (2006.01), A61K 33/06 (2006.01), A61K 33/32 (2006.01), A61K 35/60 (2006.01), A61K 47/00 (2006.01)
Applicants: BIOSYNTRX, INC. [US/US]; 151-A Riverchase Way, Lexington, SC 29072 (US) (For All Designated States Except US).
THORNTON, Spencer, P. [US/US]; (US) (For US Only).
TROYER, Ellen [US/US]; (US) (For US Only)
Inventors: THORNTON, Spencer, P.; (US).
TROYER, Ellen; (US)
Agent: HARDAWAY, John, B., III; Nexsen Pruet Jacobs & Pollard, LLC, P.O. Box 10107, Greenville, SC 29603 (US)
Priority Data:
60/396,222 17.07.2002 US
Title (EN) TREATMENT FOR DRY EYE SYNDROME
(FR) TRAITEMENT DU SYNDROME DE L'OEIL SEC
Abstract: front page image
(EN)A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term 'nutrient cofactor' refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.
(FR)Une nouvelle formulation permet de traiter de nombreux processus inflammatoires sous-jacents responsables du syndrome de l'oeil sec. La formulation, lorsqu'elle est notamment administrée par voie orale, comprend un mélange optimal d'acides gras essentiels omega-3 et omega-6 ainsi que des cofacteurs nutritifs nécessaires pour améliorer la conversion métabolique associée à la prostaglandine anti-inflammatoire de la série E-one, associée spécifiquement aux larmes (PGE1). Dans ce contexte, le terme 'cofacteur nutritif' se réfère à un composé qui soutient et améliore la transformation d'acide linoléique en acide gamma-linoléique. En outre, la formulation inhibe la production de composés pro-inflammatoires ainsi que la croissance de pathogènes viraux et bactériens du film pour larmes à trois couches.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)